If you want to distinguish your goods, services or both from those of another company, you may need a trademark or trade name. Find out what they are, what their registration procedure is and what it involves.
Information on the deadlines for filing applications for transformation of European Union trademarks into Spanish national trademarks. See more
If you have a new device, product or procedure that solves a technical problem or has a practical advantage, there are different ways to protect it in Spain and other countries. Find out how.
Does your innovation lie in the aesthetics, ornamentation or appearance of your product? Protect it through industrial design. Find out what rights registration confers and how to proceed.
Geographical indications protect the name of a product that has a specific geographical origin and owes its qualities, characteristics or reputation to its particular origin. Find out what they are, how the registration process works and what benefits they provide.
Patents published worldwide are a valuable source of scientific, technical and commercial information.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
If you are an entrepreneur or a company and you want to boost and improve the profitability of your business by adequately protecting the intangible assets of your organisation, in this space you will find what you need.
349
results.
Updated on
14/09/2026 [08:02:00]
Results 100 to 125 of 349
Absstract of: WO2025035206A1
The invention describes a transgenic, non-human animal model, for testing post-natal, conditionally inducible plasmalogen deficiency. The animal model's genome is equipped with a gene that is capable of regulating the plasmalogen biosynthetic pathway, where the gene has a regulatory region. Within the regulatory region there is at least one conditionally inducible gene editing site that blocks the expression of the gene when edited. The genome also has a nucleic acid editing sequence integrated at a separate locus from the gene which encodes a gene product. The gene product edits the gene editing site when conditionally induced that eventually down-regulates or disrupts the plasmalogen biosynthetic pathway. Methods and uses involving the transgenic, non-human animal model are also provided.
Absstract of: KR20260127477A
0001a 본 발명은 8주령 마우스의 흑색질에 알파-시누클레인 돌연변이 유전자를 갖는 바이러스 AAV-A53T를 흑색질에 정위 주입하여 파킨슨병 모델을 유도하는 단계(1); 상기 (1)단계의 바이러스 주입 2주 후, MPTP를 주입하여 미토콘드리아 기능부전을 더 유도하는 단계(2); 및 상기 (2)단계의 MPTP 주입 8일째부터 3일 간격으로 레보도파 및 카르비도파를 1일 2회 정맥주입하여 운동이상증을 유도하는 단계(3);를 포함하는 것을 특징으로 하는 레보도파로 유도된 운동이상증 마우스 동물 모델 구축 방법을 제공하며, 이전의 이상운동증 마우스 모델과 비교하여 레보도파에 의하여 유도된 비정상적인 불수의 운동이 현저히 증가된 모델을 제공함으로써 이상운동증의 치료제 연구에 기여할 수 있다.
Absstract of: KR20160146760A
0001 An anti-aging agent derived from a natural product is provided. At least one selected from the group consisting of imidazolidine peptides and metabolites thereof. The present invention also provides an agent for improving neuropsychological function comprising at least one selected from the group consisting of imidazocidepeptides and metabolites thereof as an active ingredient. The present invention is also directed to an agent for modulating the expression of a transporter, such as SLC23A2, containing at least one selected from the group consisting of imidadocidepeptides and metabolites thereof, an imidazocidepeptide and a metabolite thereof An agent for controlling the concentration of cytokine such as IP-10 containing at least one in blood, an expression analysis method for detecting improvement or deformation of neuropsychological function, a kit for detecting improvement or deformation of neuropsychological function .
Absstract of: CN122609706A
本发明属于及医学诊断领域，具体而言，涉及阿尔茨海默病的诊断标志物及其应用。具体地，本发明提供了用于诊断阿尔茨海默病的靶标及其检测方法。更具体地，本发明涉及用于检测样品中UBE2D1基因表达水平的试剂在制备用于诊断阿尔茨海默病或预测阿尔茨海默病风险的组合物或试剂盒中的用途，其中，所述用于检测样品中UBE2D1基因表达水平的试剂包括：用于检测样品中UBE2D1基因的mRNA水平的试剂，用于检测样品中泛素结合酶E2D1水平或泛素结合酶E2D1相关调控蛋白水平的试剂，用于检测UBE2D1基因CpG岛甲基化水平的试剂，或其任意组合。
Absstract of: CN122604364A
0001 本发明提供了一种皮肤间质液中褪黑素的在体检测微针贴片技术及其制备方法，涉及生物医用材料和器械技术领域。本发明提供了一种检测皮肤间质液中褪黑素的体外微针贴片的制备方法，包括以下步骤：将固体微针贴片放入浓度为2~100 μg/mL兔抗人褪黑素IgG溶液中进行包被，得体外微针贴片；所述固体微针贴片选自聚苯乙烯微针贴片或环氧树脂微针贴片。本发明制备方法能够使得体外微针贴片定量检测皮肤间质液中微量的、特定的褪黑素蛋白，具有高灵敏度、高准确性。
Absstract of: CN122612931A
0001 本发明涉及绝经后女性认知障碍诊断技术领域，公开了一种用于诊断或辅助诊断绝经后女性认知障碍的试剂盒及应用。该试剂盒包括用于检测血浆中GFAP、p‑tau181、Orexin‑A等生物标志物表达水平的检测试剂。本发明首次发现并验证了GFAP、p‑tau181等生物标志物在更年期女性认知障碍患者中显著高表达，可作为诊断或辅助诊断的标志物，为绝经后女性认知障碍的早期诊断提供了一种新的、非侵入性的检测手段。
Absstract of: CN122612933A
0001 本发明公开了一种血清α‑突触核蛋白种子体外扩增检测方法、试剂盒及其应用，属于生物医学领域。本发明提供的血清α‑突触核蛋白种子体外扩增检测方法包括以下步骤：将待测血清裂解，离心后收集第一上清液；所述第一上清液经有机溶剂萃取脂质，收集水相；所述水相加入蛋白酶K消化，再次离心后收集第二上清液；所述第二上清液经超滤后收集截留液，得到预处理后的种子富集血清样本；将所述预处理后的种子富集血清样本加入反应液中进行SAA扩增反应。本发明基于新的血清预处理思路和优化的SAA扩增反应条件，提出了一种新的血清α‑突触核蛋白种子体外扩增检测方法及配套试剂盒，以满足标准化、高通量、跨中心一致性的临床检测需求。
Absstract of: CN122612935A
本发明提供甘油磷脂代谢物在阿尔茨海默病中的应用。本发明从运动重塑5×FAD小鼠粪便代谢谱为切入点，系统分析了运动干预后代谢网络的整体变化特征，结果证实4种特定的甘油磷脂代谢物（PC(18:0/0:0)、PC(18:1(11Z)/0:0)、PC(0:0/16:0)或PC(16:0/0:0)）是运动调控肠脑病理的重要代谢信号分子，具有开发成阿尔茨海默病诊断试剂盒及治疗阿尔茨海默病药物的潜力。
Absstract of: US20260242759A1
0000 The present invention relates to G protein peptidomimetics, in particular Gprotein peptidomimetics, capable of stabilizing a GPCR, in particular a G
protein-coupled receptor, in an active conformational state. The G protein peptidomimetics are derived from the α<5 >helix of Gα
protein or mini-G
protein, in particular they arise from modifications of peptides comprising or consisting of the amino acid sequence set forth in SEQ ID NO:13 or SEQ ID NO:14. The invention further provides complexes of the G protein peptidomimetics and a GPCR, fusion polypeptides of a GPCR and the G protein peptidomimetics and compositions comprising the same. Further disclosed herein are uses of the G protein peptidomimetics, complexes, fusion polypeptides and compositions for determining the structure of a GPCR conformer, for screening for compounds capable of specifically binding to a GPCR conformer and as allosteric modulator of a GPCR and as a biosensor.
Absstract of: WO2026174031A1
A method for identifying RNA patterns in diagnosis and treatment of thoracic aortic aneurysm disease includes performing RNA sequencing on samples; analyzing the RNA sequencing data with the performance of differential gene expression analysis focusing on differentially regulated pathways to reveal complex regulatory mechanisms; developing a machine learning model to integrate pathway-level interactions; and combining pathway- specific analysis of the RNA patterns with the machine learning model to generate predictions identifying patients likely to be susceptible to thoracic aortic aneurysm disease.
Absstract of: AU2026210844A1
The disclosure relates to methods of diagnosis and prognosis, compositions for immunotherapies, methods of improving said compositions, and immunotherapies using the same (e.g., T cells, non- T cells, TCR-based therapies, CAR-based therapies, bispecific T-cell engagers (BiTEs), and/or immune checkpoint blockade). ul u l
Absstract of: US20260243777A1
0000 The present disclosure provides a range of compositions and methods for enriching subsets of complex biological samples. Aspects of the present disclosure provide peptide-functionalized particles comprising affinities for subsets of biomolecules from complex biological samples. The present disclosure further provides methods for utilizing functionalized particles to fractionate and analyze complex biological samples.
Absstract of: US20260243781A1
A method of measuring oxidative stress in a cell or tissue sample, the method including the steps of: (i) treating the cell or tissue sample in a medium; (ii) collecting a portion of the medium; (iii) measuring amounts of glutathione in the cell or tissue sample; and (iv) measuring amounts of reactive oxygen species (ROS) in the media portion collected in step (ii), step (iii) being carried out immediately after steps (i) and (ii), and step (iv) being carried out simultaneously with step (iii) or within 6 hours of step (iii) including assay time if the collected media portion is stored at about 0-8° C. until step (iv) is carried out.
Absstract of: US20260242441A1
Described herein are methods of reducing CD3-dependent T cell signaling in a subject in need thereof. Also described are method of increasing T-regulatory (Treg) cells, or decreasing T-helper 17 (Th17) cells. These methods involve administering butyrophilin A2 (BTN2A2), a BTN2A2 fragment thereof, a BTN2A2-related isoform, or a BTN2A2-related isoform fragment, or a conjugate or fusion polypeptide comprising any of the foregoing to the subject. These methods are beneficial for patients with autoimmune disorders and inflammatory disorders such as allergy, asthma, glomerulonephritis, inflammatory bowel disease, rheumatoid arthritis, an autoimmune or inflammatory neurological disease, antibody mediated transplant rejection, infantile cholestasis, haemophagocytic lymphohistiocytosis, erythrocytic haemophagocytosis, malnutrition, systemic lupus erythematosus (lupus), psoriasis, myasthenia gravis or HIV. Further described are fusion proteins having BTN2A2 and an Fc domain.
Absstract of: US20260242753A1
The present invention relates to novel therapeutic compositions and methods for treating cancer. In particular, the use of proteinaceous inhibitors, including novel bicyclic peptide inhibitors, for use in treating cancer.
Absstract of: US20260243761A1
The present invention provides a molecular probe functionalized element comprising a solid base element, a first layer comprising a linker A, a second layer comprising a peptide compound, a third layer comprising a linker B, and a fourth layer comprising a molecular probe, wherein the peptide compound is covalently bound to the solid base element via linker A and the molecular probe is covalently bound to the peptide compound via linker B. The present invention also provides a process for preparing the molecular probe functionalized element and a device comprising the molecular probe functionalized element such as an optical biosensor. Further, the present invention provides a method for detecting a biomarker comprising a) bringing into contact the molecular probe functionalized element with a sample suspected to comprise a target analyte; b) detecting the biomarker based on an interaction between the molecular probe and the target analyte. The present invention also provides a use of the molecular probe functionalized element or of the device for one or more of: a companion diagnostic test; diagnosing Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, Diabetes, Huntington, Prion disease, or a tumor in a patient; monitoring of therapy of patients with Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, Diabetes, Huntington, Prion disease, or a tumor; and screening of drugs for the treatment of Alzheimer's disease, Parkinson's disease
Absstract of: US20260241002A1
Populations of CAR T cells that exhibit reduced trogocytosis are disclosed, as well as methods for making such cells and methods of using such cells in the treatment of cancer. A reduction in trogocytosis is achieved by inhibiting Cathepsin B in the CAR T cells and/or inducing ubiquitylation of cancer antigens taken up by the CAR T cells.
Absstract of: US20260243757A1
0000 There is provided a composition comprising a secretome obtained by culturing an immune progenitor cell in the presence of an agent that activates the immune cell progenitor to an activated immune cell. Also provided is a composition for use in tissue regeneration, a method of generating a macrophage-derived secretome, a method of screening a drug and a method of culturing a proliferative cell.
Absstract of: US20260240871A1
A composition includes a lysosomal ABCA1 inhibitor. The composition inhibits the transport of cellular ABCA1 to lysosomes or suppresses ABCA1 within lysosomes, by including the lysosomal ABCA1 inhibitor, thereby inhibiting lysosomal cholesterol accumulation and the production of senescence-associated secretory phenotype (SASP) factors. Therefore, the composition can be used for inhibit age-related inflammation, and prevent, improve or treat age-related musculoskeletal disorders.
Absstract of: WO2026173983A1
The present invention provides methods and biomarkers useful for detecting, diagnosing and treating Alzheimer's Disease. The biomarkers for diagnoses may be used to develop treatment plans for subjects. The methods may be used to diagnose a subject prior to clinical onset of symptoms and may allow for early treatment which may slow progression of the disease.
Absstract of: WO2026174301A1
The present disclosure relates to compositions and methods for regulating lipokines in age-related disorders and methods of use thereof.
Absstract of: WO2026172292A1
The disclosed multiple-sample lateral flow system, device and method leverages multiple biological samples, lateral flow test and communication module (such as Bluetooth) for accurately detecting biomarkers related to one or more medical conditions. The multiple-sample lateral flow system comprises an integrated multiple test strip (IMTS) and device. The IMTS, configured to receive and process at least two biological samples, comprises first and second test zones configured to detect first and second sets of biomarkers specific to first and second biological samples that are indicative of at least one first medical condition, second medical condition. The device comprises a strip receiving unit to receive the integrated multiple test strip; an imaging sensor configured to capture images of the integrated multiple test strip; and a communication module configured to transmit the captured images to a processing unit for analysis and identification of the one or more medical conditions.
Absstract of: WO2026171791A1
The disclosure relates to a system for multiplex detection of analytes by primary translatable complexes. This refers to complexes of an antigen-specific primary antibody and oligonucleotides are used to detect multiple antigens of interest in a simultaneous manner. The linkage between primary antibody and oligonucleotides is achieved by using avidin-biotin system. Each of the multiple complexes are formed in individual reaction tubes and added simultaneously to biological specimens. The presence of antigens can be identified via various options using complementary oligonucleotides. This allows a simultaneous detection of analytes.
Absstract of: US20260243762A1
0000 A multimodal lateral flow assay (LFA) system for non-invasive biomarker monitoring is provided. The system includes a multimodal LFA strip having a sample-loading region for receiving a biological sample, a conjugate region containing triple-mode probes, and a membrane zone with immobilized capture and secondary antibodies that form respective test and control lines upon binding the probes. The triple-mode probes generate colorimetric, fluorescence, and surface-enhanced Raman scattering (SERS) signals. A laser-emitting module illuminates the membrane zone to excite fluorescence and SERS responses, which are detected by one or more optical detection devices. A processor performs multimodal signal mapping by analyzing fluorescence and SERS outputs to determine the quantitative concentration of the biomarker in the sample. The system enables sensitive, quantitative, and non-invasive detection of biomarkers across multiple optical modalities.
Nº publicación: WO2026170288A1 20/08/2026
Applicant:
SALAHANDISH RAZIEH [CA]
HAGHANI ELNAZ [CA]
ROZENBLAT SHAHAK [CA]
SALAHANDISH, Razieh
HAGHANI, Elnaz
ROZENBLAT, Shahak
Absstract of: WO2026170288A1
Various embodiments of a wearable device for disease detection are described herein. The wearable devices include a plurality of layers including an adhesive layer for affixing the wearable device to a subject's skin and a plurality of patterned layers, each patterned layer having a sensing pattern defined thereon. When the patterned layers are assembled, the sensing patterns cooperate to define: inlet chambers adapted to receive sweat droplets, each inlet chamber having antibodies conjugated to a detection medium adapted to bind to a corresponding biomarker of interest in the sweat droplets, sensing chambers, each sensing chamber receiving the sweat droplets from at least one inlet chamber via a microchannel through capillary action and adapted to sense a corresponding biomarker of interest by binding at least a portion of the conjugate molecules associated with the corresponding biomarker, and a control chamber in fluid communication with the sensing chambers via outlet channels.
BOPI
Electronic site
